162 related articles for article (PubMed ID: 32698792)
1. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox.
Amano S; Kaino S; Shinoda S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2020 Jul; 20(1):681. PubMed ID: 32698792
[TBL] [Abstract][Full Text] [Related]
2. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo.
Zhou N; Cui Y; Zhu R; Kuang Y; Ma W; Hou J; Zhu Y; Chen S; Xu X; Tan K; Cao P; Duan X; Fan Y
Gynecol Oncol; 2022 Jul; 166(1):126-137. PubMed ID: 35688655
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells.
Calabrese C; Panuzzo C; Stanga S; Andreani G; Ravera S; Maglione A; Pironi L; Petiti J; Shahzad Ali MS; Scaravaglio P; Napoli F; Fava C; De Gobbi M; Frassoni F; Saglio G; Bracco E; Pergolizzi B; Cilloni D
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33081324
[TBL] [Abstract][Full Text] [Related]
5. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
[TBL] [Abstract][Full Text] [Related]
6. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
Samara A; Shapira S; Lubin I; Shpilberg O; Avigad S; Granot G; Raanani P
Br J Haematol; 2021 Feb; 192(4):747-760. PubMed ID: 33521925
[TBL] [Abstract][Full Text] [Related]
7. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth
Shinoda S; Kaino S; Amano S; Harima H; Matsumoto T; Fujisawa K; Takami T; Yamamoto N; Yamasaki T; Sakaida I
Oncotarget; 2018 Jun; 9(47):28434-28444. PubMed ID: 29983871
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility.
Nakajima A; Tomimoto A; Fujita K; Sugiyama M; Takahashi H; Ikeda I; Hosono K; Endo H; Yoneda K; Iida H; Inamori M; Kubota K; Saito S; Nakajima N; Wada K; Nagashima Y; Nakagama H
Cancer Sci; 2008 Oct; 99(10):1892-900. PubMed ID: 19016747
[TBL] [Abstract][Full Text] [Related]
9. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of small molecule Rac1 inhibitors.
Arnst JL; Hein AL; Taylor MA; Palermo NY; Contreras JI; Sonawane YA; Wahl AO; Ouellette MM; Natarajan A; Yan Y
Oncotarget; 2017 May; 8(21):34586-34600. PubMed ID: 28410221
[TBL] [Abstract][Full Text] [Related]
11. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
[TBL] [Abstract][Full Text] [Related]
12. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status.
Lee DH; Jang PS; Chung NG; Cho B; Jeong DC; Kim HK
Exp Hematol; 2013 Jun; 41(6):539-46. PubMed ID: 23415674
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells.
Tataranni T; Mazzoccoli C; Agriesti F; De Luca L; Laurenzana I; Simeon V; Ruggieri V; Pacelli C; Della Sala G; Musto P; Capitanio N; Piccoli C
Stem Cell Res Ther; 2019 Jun; 10(1):171. PubMed ID: 31196186
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinoma.
Qin J; Zhou C; Zhu M; Shi S; Zhang L; Zhao Y; Li C; Wang Y; Wang Y
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101907. PubMed ID: 32619712
[TBL] [Abstract][Full Text] [Related]
15. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
[TBL] [Abstract][Full Text] [Related]
16. Rac1 and Rac3 isoform activation is involved in the invasive and metastatic phenotype of human breast cancer cells.
Baugher PJ; Krishnamoorthy L; Price JE; Dharmawardhane SF
Breast Cancer Res; 2005; 7(6):R965-74. PubMed ID: 16280046
[TBL] [Abstract][Full Text] [Related]
17. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.
Jaffe T; Schwartz B
Int J Cancer; 2008 Dec; 123(11):2543-56. PubMed ID: 18767036
[TBL] [Abstract][Full Text] [Related]
18. The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
Tury S; Assayag F; Bonin F; Chateau-Joubert S; Servely JL; Vacher S; Becette V; Caly M; Rapinat A; Gentien D; de la Grange P; Schnitzler A; Lallemand F; Marangoni E; Bièche I; Callens C
J Pathol; 2018 Sep; 246(1):103-114. PubMed ID: 29876931
[TBL] [Abstract][Full Text] [Related]
19. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
20. BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study.
Makrodouli E; Oikonomou E; Koc M; Andera L; Sasazuki T; Shirasawa S; Pintzas A
Mol Cancer; 2011 Sep; 10():118. PubMed ID: 21943101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
